Barbara C. Tilley, PhD; Graciela S. Alarcon, MD; Stephen P. Heyse, MD, MPH; David E. Trentham, MD; Rosemarie Neuner, MD; David A. Kaplan†, MD; Daniel O. Clegg, MD; James C. C. Leisen, MD; Lenore Buckley, MD; Sheldon M. Cooper, MD; Howard Duncan, MD; Stanley R. Pillemer, MD; Marilyn Tuttleman, MS; Sarah E. Fowler, PhD
Tilley B., Alarcon G., Heyse S., Trentham D., Neuner R., Kaplan† D., Clegg D., Leisen J., Buckley L., Cooper S., Duncan H., Pillemer S., Tuttleman M., Fowler S.; Minocycline in Rheumatoid Arthritis: A 48-Week, Double-Blind, Placebo-Controlled Trial. Ann Intern Med. 1995;122:81-89. doi: 10.7326/0003-4819-122-2-199501150-00001
Download citation file:
Published: Ann Intern Med. 1995;122(2):81-89.
To assess the safety and efficacy of minocycline in the treatment of rheumatoid arthritis.
A double-blind, randomized, multicenter, 48-week trial of oral minocycline (200 mg/d) or placebo.
6 clinical centers in the United States.
219 adults with active rheumatoid arthritis who had previous limited treatment with disease-modifying drugs.
As the primary outcomes, 60 diarthrodial joints were examined for tenderness, and 58 joints were examined for swelling (hips excluded). Grip strength, evaluator's global assessment, morning stiffness, Modified Health Assessment Questionnaire, patient's global assessment, hematocrit, erythrocyte sedimentation rate, platelet count, and IgM rheumatoid factor levels were also assessed; radiographs of both hands and wrists were taken.
109 and 110 patients were randomly assigned to receive minocycline and placebo, respectively. At entry, demographic, clinical, and laboratory measurements were similar in both groups. Most patients had mild to moderate disease activity and some evidence of destructive disease. At the week 48 visit, 79% of the minocycline group and 78% of the placebo group continued to receive the study medication. At 48 weeks, more patients in the minocycline group than in the placebo group showed improvement in joint swelling (54% and 39%) and joint tenderness (56% and 41%) (P < 0.023 for both comparisons). The minocycline group also showed greater improvement in hematocrit, erythrocyte sedimentation rate, platelet count, and IgM rheumatoid factor levels (all P values < 0.001), and more patients receiving minocycline had laboratory values within normal ranges at 48 weeks. For the remaining outcomes, P values ranged from 0.04 to 0.76, all greater than the critical value of 0.005 (Bonferroni adjustment for multiple comparisons). The frequency of reported side effects was similar in both groups, and no serious toxicity occurred.
Minocycline was safe and effective for patients with mild to moderate rheumatoid arthritis. Its mechanisms of action remain to be determined.
For current author affiliations, see end of text.
*For members of the MIRA Trial Group, see the Appendix. For current author affiliations, see end of text.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Rheumatology, Rheumatoid Arthritis, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only